JP2004527512A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004527512A5 JP2004527512A5 JP2002573761A JP2002573761A JP2004527512A5 JP 2004527512 A5 JP2004527512 A5 JP 2004527512A5 JP 2002573761 A JP2002573761 A JP 2002573761A JP 2002573761 A JP2002573761 A JP 2002573761A JP 2004527512 A5 JP2004527512 A5 JP 2004527512A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- formula
- alcohol
- treatment
- mmp12
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- -1 alkyl carbamate Chemical compound 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 101000577881 Homo sapiens Macrophage metalloelastase Proteins 0.000 description 3
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000004422 alkyl sulphonamide group Chemical group 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 description 1
- 101000990908 Homo sapiens Neutrophil collagenase Proteins 0.000 description 1
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 229910003844 NSO2 Inorganic materials 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 108010003059 aggrecanase Proteins 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0100903A SE0100903D0 (sv) | 2001-03-15 | 2001-03-15 | Compounds |
| PCT/SE2002/000479 WO2002074752A1 (en) | 2001-03-15 | 2002-03-13 | Metalloproteinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004527512A JP2004527512A (ja) | 2004-09-09 |
| JP2004527512A5 true JP2004527512A5 (https=) | 2006-01-05 |
Family
ID=20283375
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002573761A Pending JP2004527512A (ja) | 2001-03-15 | 2002-03-13 | メタロプロテイナーゼ阻害剤 |
| JP2002573758A Pending JP2004523582A (ja) | 2001-03-15 | 2002-03-13 | メタロプロテイナーゼ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002573758A Pending JP2004523582A (ja) | 2001-03-15 | 2002-03-13 | メタロプロテイナーゼ阻害剤 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20040116486A1 (https=) |
| EP (2) | EP1370535A1 (https=) |
| JP (2) | JP2004527512A (https=) |
| KR (2) | KR20030082988A (https=) |
| CN (2) | CN1509274A (https=) |
| AR (1) | AR035444A1 (https=) |
| AU (1) | AU2002237633B2 (https=) |
| BR (2) | BR0207985A (https=) |
| CA (2) | CA2440475A1 (https=) |
| CZ (2) | CZ20032501A3 (https=) |
| EE (2) | EE200300450A (https=) |
| HU (2) | HUP0400328A3 (https=) |
| IL (2) | IL157650A0 (https=) |
| IS (2) | IS6945A (https=) |
| MX (2) | MXPA03008187A (https=) |
| MY (1) | MY129188A (https=) |
| NO (2) | NO326088B1 (https=) |
| NZ (2) | NZ528108A (https=) |
| PL (2) | PL365107A1 (https=) |
| RU (2) | RU2293730C2 (https=) |
| SE (1) | SE0100903D0 (https=) |
| SK (2) | SK10912003A3 (https=) |
| UA (2) | UA77169C2 (https=) |
| WO (2) | WO2002074752A1 (https=) |
| ZA (2) | ZA200306738B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO5300399A1 (es) | 2000-02-25 | 2003-07-31 | Astrazeneca Ab | Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen |
| US7005439B2 (en) * | 2000-06-20 | 2006-02-28 | Astrazeneca Ab | Compounds |
| SE0100902D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| SE0100903D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| US6890915B2 (en) | 2001-05-25 | 2005-05-10 | Bristol-Myers Squibb Pharma Company | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| SE0103710D0 (sv) | 2001-11-07 | 2001-11-07 | Astrazeneca Ab | Compounds |
| MY131170A (en) * | 2002-03-28 | 2007-07-31 | Nissan Chemical Ind Ltd | Therapeutic agent for glomerular disease |
| SE0202539D0 (sv) | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
| SE0202692D0 (sv) * | 2002-09-11 | 2002-09-11 | Astrazeneca Ab | Compounds |
| GB0221246D0 (en) * | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
| FR2845000B1 (fr) | 2002-09-27 | 2005-05-27 | Oreal | Utilisation d'un compose heterocyclique ou de l'un de ses sels pour stimuler ou induire la pousse des cheveux et/ou freiner leur chute |
| US7648992B2 (en) | 2004-07-05 | 2010-01-19 | Astrazeneca Ab | Hydantoin derivatives for the treatment of obstructive airway diseases |
| SE0401763D0 (sv) * | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Compounds |
| SE0401762D0 (sv) * | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Novel compounds |
| JP5042833B2 (ja) * | 2004-08-19 | 2012-10-03 | クエスト ファーマシューティカル サーヴィシーズ | マクロファージエラスターゼの阻害剤としての５−［３−（４−ベンジルオキシフェニルチオ）−フラ−２−イル］−イミダゾリジン−２，４−ジオン及び類似体 |
| JPWO2006051937A1 (ja) * | 2004-11-15 | 2008-05-29 | 塩野義製薬株式会社 | ヘテロ５員環誘導体 |
| SE0403086D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
| SE0403085D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
| TW200740769A (en) | 2006-03-16 | 2007-11-01 | Astrazeneca Ab | Novel process |
| AU2007249924B2 (en) | 2006-05-08 | 2013-07-04 | Ariad Pharmaceuticals, Inc. | Acetylenic heteroaryl compounds |
| BRPI0710331A2 (pt) | 2006-05-08 | 2012-03-20 | Ariad Pharmaceuticals, Inc | Compostos heteroarila monocíclicos para tratamento de câncer e composição |
| TW200831488A (en) * | 2006-11-29 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
| ES2313841B1 (es) * | 2007-06-26 | 2010-01-12 | Proyecto De Biomedicina Cima, S.L. | Composiciones para tratamiento anti-fibrinolitico. |
| EP2365809B8 (en) | 2008-11-12 | 2018-10-10 | Ariad Pharmaceuticals, Inc. | Pyrazinopyrazines and derivatives as kinase inhibitors |
| US8492556B2 (en) * | 2011-11-10 | 2013-07-23 | Allergan, Inc. | 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| EP2907512A1 (en) | 2014-02-14 | 2015-08-19 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Inhibitors of MMP-12 as antiviral Agents |
| EP3555064B9 (en) | 2016-12-16 | 2023-03-01 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| SI3793995T1 (sl) | 2018-05-15 | 2024-05-31 | Foresee Pharmaceuticals Usa, Inc. | Zaviralci matrične metaloproteinaze (mmp)in načini njihove uporabe |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2745875A (en) * | 1953-06-30 | 1956-05-15 | Hoechst Ag | Preparation of nu-acylamino-phenylpropane diols |
| US3452040A (en) * | 1966-01-05 | 1969-06-24 | American Home Prod | 5,5-disubstituted hydantoins |
| US3529019A (en) * | 1968-04-23 | 1970-09-15 | Colgate Palmolive Co | Alkylaryloxy alanines |
| US3849574A (en) * | 1971-05-24 | 1974-11-19 | Colgate Palmolive Co | Alpha-substituted-beta-arylthioalkyl amino-acids,for increasing heart rate |
| US4315031A (en) * | 1977-09-01 | 1982-02-09 | Science Union Et Cie | Thiosubstituted amino acids |
| GB1601310A (en) * | 1978-05-23 | 1981-10-28 | Lilly Industries Ltd | Aryl hydantoins |
| JPS61212292A (ja) * | 1985-03-19 | 1986-09-20 | Mitsui Toatsu Chem Inc | Ｄ−α−アミノ酸の製造方法 |
| JPH0597814A (ja) * | 1991-10-02 | 1993-04-20 | Ajinomoto Co Inc | ５−（ヒドロキシメチル）ヒダントイン誘導体の製法 |
| PH31245A (en) * | 1991-10-30 | 1998-06-18 | Janssen Pharmaceutica Nv | 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives. |
| US5308853A (en) * | 1991-12-20 | 1994-05-03 | Warner-Lambert Company | Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties |
| US5246943A (en) * | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
| EP0640594A1 (en) * | 1993-08-23 | 1995-03-01 | Fujirebio Inc. | Hydantoin derivative as metalloprotease inhibitor |
| US6166041A (en) * | 1995-10-11 | 2000-12-26 | Euro-Celtique, S.A. | 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma |
| DE19540027A1 (de) * | 1995-10-27 | 1997-04-30 | Gruenenthal Gmbh | Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe |
| WO1997019075A1 (en) * | 1995-11-22 | 1997-05-29 | Darwin Discovery Limited | Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (mmp) and/or tumour necrosis factor (tnf) |
| GB9616643D0 (en) * | 1996-08-08 | 1996-09-25 | Chiroscience Ltd | Compounds |
| US5919790A (en) * | 1996-10-11 | 1999-07-06 | Warner-Lambert Company | Hydroxamate inhibitors of interleukin-1β converting enzyme |
| ATE212619T1 (de) * | 1996-10-22 | 2002-02-15 | Upjohn Co | Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren |
| IL132170A0 (en) * | 1997-05-06 | 2001-03-19 | Novo Nordisk As | Novel heterocyclic compounds |
| DE59802394D1 (de) * | 1997-05-09 | 2002-01-24 | Hoechst Ag | Substituierte Diaminocarbonsäuren |
| NZ501166A (en) * | 1997-07-31 | 2001-12-21 | Abbott Lab | Reverse hydroxamate-containing compounds and their use as inhibitors of matrix metalloproteinases |
| RU2208609C2 (ru) * | 1998-02-04 | 2003-07-20 | Новартис Аг | Сульфониламинопроизводные, которые ингибируют разлагающие матрикс металлопротеиназы |
| US6329418B1 (en) * | 1998-04-14 | 2001-12-11 | The Procter & Gamble Company | Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
| EP1077974A1 (en) * | 1998-05-14 | 2001-02-28 | Du Pont Pharmaceuticals Company | Substituted aryl hydroxamic acids as metalloproteinase inhibitors |
| AU4692399A (en) * | 1998-06-17 | 2000-01-05 | Du Pont Pharmaceuticals Company | Cyclic hydroxamic acids as metalloproteinase inhibitors |
| US6339101B1 (en) * | 1998-08-14 | 2002-01-15 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders |
| DK1004578T3 (da) * | 1998-11-05 | 2004-06-28 | Pfizer Prod Inc | 5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater |
| EP1150975A1 (en) * | 1998-12-31 | 2001-11-07 | Aventis Pharmaceuticals Inc. | 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12 |
| US6340691B1 (en) * | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
| US20020006920A1 (en) * | 1999-07-22 | 2002-01-17 | Robinson Ralph Pelton | Arylsulfonylamino hydroxamic acid derivatives |
| EP1078923B1 (en) * | 1999-08-02 | 2006-03-08 | F. Hoffmann-La Roche Ag | Process for the preparation of benzothiophene derivatives |
| KR20020060160A (ko) * | 1999-08-12 | 2002-07-16 | 파마시아 이탈리아 에스.피.에이. | 3(5)-아미노-피라졸 유도체, 이의 제조 방법 및항종양제로서의 이의 용도 |
| US6525202B2 (en) * | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| US20020065219A1 (en) * | 2000-08-15 | 2002-05-30 | Naidu B. Narasimhulu | Water soluble thiazolyl peptide derivatives |
| US20020091107A1 (en) * | 2000-09-08 | 2002-07-11 | Madar David J. | Oxazolidinone antibacterial agents |
| JP2004527511A (ja) * | 2001-03-15 | 2004-09-09 | アストラゼネカ・アクチエボラーグ | メタロプロテイナーゼ阻害剤 |
| SE0100902D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| SE0100903D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| US6890915B2 (en) * | 2001-05-25 | 2005-05-10 | Bristol-Myers Squibb Pharma Company | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| GB0114004D0 (en) * | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
| SE0103710D0 (sv) * | 2001-11-07 | 2001-11-07 | Astrazeneca Ab | Compounds |
| SE0202539D0 (sv) * | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
| GB0221246D0 (en) * | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
| TWI220073B (en) * | 2003-07-24 | 2004-08-01 | Au Optronics Corp | Method for manufacturing polysilicon film |
| US7648992B2 (en) * | 2004-07-05 | 2010-01-19 | Astrazeneca Ab | Hydantoin derivatives for the treatment of obstructive airway diseases |
| SE0401763D0 (sv) * | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Compounds |
| SE0403086D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
| TW200831488A (en) * | 2006-11-29 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
-
2001
- 2001-03-15 SE SE0100903A patent/SE0100903D0/xx unknown
-
2002
- 2002-03-13 RU RU2003127736/04A patent/RU2293730C2/ru not_active IP Right Cessation
- 2002-03-13 NZ NZ528108A patent/NZ528108A/en unknown
- 2002-03-13 WO PCT/SE2002/000479 patent/WO2002074752A1/en not_active Ceased
- 2002-03-13 IL IL15765002A patent/IL157650A0/xx unknown
- 2002-03-13 IL IL15765802A patent/IL157658A0/xx unknown
- 2002-03-13 BR BR0207985-2A patent/BR0207985A/pt not_active IP Right Cessation
- 2002-03-13 UA UA2003098167A patent/UA77169C2/uk unknown
- 2002-03-13 US US10/471,501 patent/US20040116486A1/en not_active Abandoned
- 2002-03-13 KR KR10-2003-7011983A patent/KR20030082988A/ko not_active Withdrawn
- 2002-03-13 CN CNA028099273A patent/CN1509274A/zh active Pending
- 2002-03-13 MX MXPA03008187A patent/MXPA03008187A/es not_active Application Discontinuation
- 2002-03-13 EE EEP200300450A patent/EE200300450A/xx unknown
- 2002-03-13 RU RU2003127731/04A patent/RU2003127731A/ru not_active Application Discontinuation
- 2002-03-13 EP EP02704033A patent/EP1370535A1/en not_active Withdrawn
- 2002-03-13 CA CA002440475A patent/CA2440475A1/en not_active Abandoned
- 2002-03-13 EE EEP200300452A patent/EE200300452A/xx unknown
- 2002-03-13 UA UA2003098169A patent/UA74624C2/uk unknown
- 2002-03-13 BR BR0208062-1A patent/BR0208062A/pt not_active IP Right Cessation
- 2002-03-13 MY MYPI20020912A patent/MY129188A/en unknown
- 2002-03-13 JP JP2002573761A patent/JP2004527512A/ja active Pending
- 2002-03-13 MX MXPA03008183A patent/MXPA03008183A/es unknown
- 2002-03-13 NZ NZ528141A patent/NZ528141A/en unknown
- 2002-03-13 CA CA002444526A patent/CA2444526A1/en not_active Abandoned
- 2002-03-13 PL PL02365107A patent/PL365107A1/xx not_active Application Discontinuation
- 2002-03-13 SK SK1091-2003A patent/SK10912003A3/sk not_active Application Discontinuation
- 2002-03-13 KR KR1020037011980A patent/KR100865836B1/ko not_active Expired - Fee Related
- 2002-03-13 CZ CZ20032501A patent/CZ20032501A3/cs unknown
- 2002-03-13 CN CNB028097890A patent/CN1313448C/zh not_active Expired - Fee Related
- 2002-03-13 SK SK1094-2003A patent/SK10942003A3/sk not_active Application Discontinuation
- 2002-03-13 EP EP02704038A patent/EP1370538A1/en not_active Withdrawn
- 2002-03-13 PL PL02364705A patent/PL364705A1/xx not_active Application Discontinuation
- 2002-03-13 HU HU0400328A patent/HUP0400328A3/hu unknown
- 2002-03-13 WO PCT/SE2002/000474 patent/WO2002074749A1/en not_active Ceased
- 2002-03-13 US US10/471,499 patent/US20040110809A1/en not_active Abandoned
- 2002-03-13 HU HU0400193A patent/HUP0400193A3/hu unknown
- 2002-03-13 CZ CZ20032498A patent/CZ20032498A3/cs unknown
- 2002-03-13 AU AU2002237633A patent/AU2002237633B2/en not_active Ceased
- 2002-03-13 JP JP2002573758A patent/JP2004523582A/ja active Pending
- 2002-03-15 AR ARP020100945A patent/AR035444A1/es unknown
-
2003
- 2003-08-28 ZA ZA200306738A patent/ZA200306738B/en unknown
- 2003-08-28 ZA ZA200306733A patent/ZA200306733B/en unknown
- 2003-09-10 IS IS6945A patent/IS6945A/is unknown
- 2003-09-11 NO NO20034027A patent/NO326088B1/no not_active IP Right Cessation
- 2003-09-11 NO NO20034032A patent/NO20034032L/no unknown
- 2003-09-11 IS IS6948A patent/IS6948A/is unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004527512A5 (https=) | ||
| US6974836B2 (en) | Diamines as modulators of chemokine receptor activity | |
| RU2128173C1 (ru) | Производные 1-бифенилметилимидазола, способ их получения и фармацевтическая композиция для лечения и профилактики гипертензии | |
| DE69322254T2 (de) | Pyridyl-substituierte imidazole | |
| EP1245568B1 (fr) | Dérives sulfonyles d'-aminoacides et leur utilisation en tant qu'inhibiteurs de dipeptidyl-peptidase IV ( DPP IV) | |
| JP4555071B2 (ja) | Ｎｏｓインヒビターとしての１−置換イミダゾール誘導体 | |
| US20050065196A1 (en) | Azole compound and medicinal use thereof | |
| US7718686B2 (en) | Imidazole variants as modulators of GABA receptor for the treatment of GI disorders | |
| US20050009812A1 (en) | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | |
| JP2009532454A (ja) | 新規ジペプチジルペプチダーゼｉｖ阻害因子およびその調製方法、ならび該阻害因子を含む医薬組成物 | |
| IE922316A1 (en) | Retroviral protease inhibitors | |
| US6117841A (en) | Substituted peptidylamine calcium channel blockers | |
| EP0532410A1 (fr) | Dérivés hétérocycliques N-substitués, comme inhibiteurs de l'angiotensive II | |
| JPH0757752B2 (ja) | 抗生物質の中間体 | |
| JP2987313B2 (ja) | 不可逆的なヒト免疫不全ウイルス（ｈｉｖ）プロテアーゼ阻害剤、中間体、組成物およびその製造方法 | |
| JPH09124609A (ja) | ベンズイミダゾール誘導体 | |
| US20080312291A1 (en) | Heterocyclic Gaba-b Modulators | |
| US7745637B2 (en) | Peptide deformylase inhibitors | |
| JPH06510766A (ja) | Ｈ．ｉ．ｖ．阻害剤としてのヘテロ環含有ペプチド同配体 | |
| SK114094A3 (en) | Peptides, method of their producing, their using and pharmaceutical preparation on their base | |
| JP4348086B2 (ja) | ペプチドデホルミラーゼ阻害剤 | |
| HU211531A9 (en) | N-(hydroxyethyl)butanediamide derivatives | |
| US7456211B2 (en) | Peptide deformylase inhibitors | |
| US6897233B2 (en) | Peptide deformylase inhibitors | |
| WO2004087643A1 (en) | Deformylase inhibitor, process for preparing the same, and antibacterial composition comprising the same |